Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/27/2025

Management of Sleep Apnea with Lexapro and Lunesta

Introduction to Treatment Options

  • The American Academy of Sleep Medicine guidelines advise caution when prescribing sedatives/hypnotics to patients with signs or symptoms of compromised respiratory function, including sleep apnea, and recommend careful monitoring for respiratory compromise 1
  • SSRIs like escitalopram are generally safer than sedating antidepressants in patients with respiratory compromise, as they belong to a class with a more favorable profile in terms of respiratory effects 1

Considerations for Lexapro Use

  • Weight gain monitoring is essential when using antidepressants, as some can induce weight gain that may exacerbate sleep apnea, with fluoxetine and sertraline associated with less weight gain than paroxetine 2
  • If insomnia is comorbid with depression, low-dose sedating antidepressants do not constitute adequate treatment of major depression, and full-dose antidepressant therapy is required 1

Lunesta Use in Sleep Apnea

  • The American Academy of Sleep Medicine guidelines emphasize caution with compromised respiratory function, and eszopiclone is contraindicated in patients with severe OSA or significant nocturnal desaturation 1
  • A systematic review found no significant worsening of OSA with eszopiclone compared to placebo, contrasting with some benzodiazepines like flurazepam and triazolam, which significantly lowered nighttime oxygen saturation 2

Clinical Application and Monitoring

  • For mild-moderate OSA with adequate oxygenation, consider eszopiclone 2-3 mg at bedtime for sleep-onset and maintenance insomnia, using the lowest effective dose and monitoring for next-morning impairment 1, 3
  • Elderly or debilitated patients should start with 1 mg, maximum 2 mg, and those with severe hepatic impairment should not exceed 1 mg or 2 mg 1
  • The FDA warns that all benzodiazepine receptor agonists carry a risk of sleep-related behaviors, and patients should be counseled about allowing appropriate sleep time, using only prescribed doses, and avoiding combination with alcohol or other sedatives 1, 3
  • Avoid eszopiclone in elderly patients with cognitive impairment due to the risk of decreased cognitive performance 3
  • Repeat polysomnography may be warranted after initiating eszopiclone to confirm no worsening of respiratory events, and patients should be assessed for residual daytime sedation and monitored for tolerance and withdrawal 1